Please upgrade your browser.
Lpath, Inc. (OTCQB: LPTND), the industry leader in bioactive lipid-targeted therapeutics, has received confirmation that its application to list the company's common stock on the NASDAQ Capital Market has been approved by the NASDAQ Stock Market, a unit of the NASDAQ OMX Group.
Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines
Multitargeted tyrosine kinase inhibitors (TKIs) (such as Sunitinib and Sorafenib) and mTOR inhibitors (such as Temsirolimus) are effective in treating metastatic clear-cell renal cell carcinoma (CCRCC), by acting on different pathways in both tumour and endothelial cells. A study of their combined effect could be of major interest.
These findings 1) demonstrate that patients with suspected inherited RCC should be examined for germline SDHB mutations, 2) suggest that all identified SDHB mutation carriers should be offered surveillance for RCC, and 3) provide a further link between familial RCC and activation of hypoxic-gene response pathways.
"Princess Alyssa," as she's known by staff and volunteers, first visited the resort when she was 3 years old and had been diagnosed with kidney cancer. After her visit, doctors found that the cancer was in remission.
Exelixis has completed the rolling submission of its New Drug Application (NDA) for cabozantinib...
“Get on the map!” Bill Bro, CEO of Chicago-based Kidney Cancer Association (KCA), encourages families that are dealing with kidney cancer to join the charity’s newest social network, KidneyCancer.ME.
The reversible posterior leukoencephalopathy syndrome is a clinical/radiological syndrome characterized by headache, seizures, impaired vision, acute hypertension, and typical magnetic resonance imaging findings. There are several reports in the literature that depict its occurrence in cancer patients.
Are the following statements myths or facts about kidney cancer?
The study is the first to provide evidence of an association between blood-borne virus infection and cancer risk in people with opioid dependency, finding an increased risk for 11 cancers. Six cancers, including prostate and breast cancer, showed a reduced risk.
mTORC1 is a validated therapeutic target for renal cell carcinoma (RCC)
|Powered by NeonCRM|